SIH Partners’s CRISPR Therapeutics CRSP Stock Holding History

SIH Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,712	Closed	-$330K	–	205
2025 Q1	$330K	Buy	+9,712	New	+$412K	0.01%	188

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIH Partners's CRSP Position: Q2 2025 in Review

SIH Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 9,712 shares — an estimated $330K sold.

SIH Partners first reported a position in CRSP in Q1 2025 and held it in 1 quarter. The position peaked at $330K in Q1 2025. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

SIH Partners reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 9,712 CRISPR Therapeutics shares in Q2 2025, an estimated $330K.
SIH Partners first reported a position in CRISPR Therapeutics in Q1 2025 and held it in 1 quarter.
SIH Partners's CRISPR Therapeutics position peaked at $330K in Q1 2025.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.